Study of KRX-0502 (Ferric Citrate) Dose Regimens in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and Iron-Deficiency Anemia
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2018
At a glance
- Drugs Ferric citrate (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms COMPASS
- Sponsors Keryx Biopharmaceuticals
- 21 Sep 2018 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
- 21 Sep 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 21 Sep 2018 Status changed from recruiting to active, no longer recruiting.